Oncology Central

The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma


Historically, treatment options for metastatic melanoma (MM) have been limited, yielding a median overall survival (OS) of 8–10 months and a 5-year survival of less than 10% [1]. These dismal results have been radically improved due to the dramatic advances in immunotherapy for MM. The immunotherapy revolution began with the CTLA-4 inhibitor ipilimumab (Bristol Myers-Squibb, NY, USA), the first medication to show an OS benefit in MM [2,3].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.